Mohit Narang, MD

Articles by Mohit Narang, MD

Brukinsa packaging | Image: BeOne Medicines

Safety Drives Decision to Move to Zanubrutinib in CLL

ByMohit Narang, MD,Hayden E. Klein

June 19th 2025

Switching From Ibrutinib to Zanubrutinib Improves Cardiac Safety and Workflow: Mohit Narang, MD

ByHayden E. Klein,Mohit Narang, MD

June 2nd 2025

Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac adverse effects and a reduced workload for Mohit Narang, MD, managing partner at Maryland Oncology Hematology.

Switching Patients With CLL From Ibrutinib for Zanubrutinib: Mohit Narang, MD

ByHayden E. Klein,Mohit Narang, MD

May 15th 2025

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton tyrosine kinase inhibitor.

Mohit Narang, MD

Articles by Mohit Narang, MD

Safety Drives Decision to Move to Zanubrutinib in CLL

Switching From Ibrutinib to Zanubrutinib Improves Cardiac Safety and Workflow: Mohit Narang, MD

Switching Patients With CLL From Ibrutinib for Zanubrutinib: Mohit Narang, MD

Latest Updated Articles

Trending on AJMC

PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency

New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq

Additional Emerging HER2-Targeted Therapies in NSCLC

Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries